These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 3689631)
41. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. Valitalo PA; van den Anker JN; Allegaert K; de Cock RF; de Hoog M; Simons SH; Mouton JW; Knibbe CA J Antimicrob Chemother; 2015 Jul; 70(7):2074-7. PubMed ID: 25766737 [TBL] [Abstract][Full Text] [Related]
42. Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches. Ordovás JP; Ronchera CL; Poveda JL; Jiménez NV; López R J Clin Pharm Ther; 1994 Feb; 19(1):47-56. PubMed ID: 8188791 [TBL] [Abstract][Full Text] [Related]
43. An approach to forecast aminoglycoside-related nephrotoxicity from routinely collected clinical data. Kubota K; Suganuma T; Sasaki T; Ishizaki T Ther Drug Monit; 1988; 10(4):410-20. PubMed ID: 3201525 [TBL] [Abstract][Full Text] [Related]
44. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Matthews I; Kirkpatrick C; Holford N Br J Clin Pharmacol; 2004 Jul; 58(1):8-19. PubMed ID: 15206987 [TBL] [Abstract][Full Text] [Related]
45. Population pharmacokinetics of tobramycin. Aarons L; Vozeh S; Wenk M; Weiss P; Follath F Br J Clin Pharmacol; 1989 Sep; 28(3):305-14. PubMed ID: 2789924 [TBL] [Abstract][Full Text] [Related]
46. [Pharmacokinetic monitoring during aminoglycoside treatment: the optimal method for individualizing the dosage of tobramycin]. Firsov AA; Manuĭlov KK; Fomina IP; Lukomskiĭ GI; Alekseeva ME Antibiot Khimioter; 1989 Dec; 34(12):915-20. PubMed ID: 2629652 [TBL] [Abstract][Full Text] [Related]
47. Once-daily versus pharmacokinetic dosing of aminoglycosides. Medicus-Bringa M; Ward G; Rice M Am J Med; 1997 Oct; 103(4):328-30. PubMed ID: 9382126 [No Abstract] [Full Text] [Related]
48. Aminoglycoside clearance is a good estimate of creatinine clearance in intensive care unit patients. Jones TE; Peter JV; Field J Anaesth Intensive Care; 2009 Nov; 37(6):944-52. PubMed ID: 20014601 [TBL] [Abstract][Full Text] [Related]
49. Comparison of the predictions of one- and two-compartment microcomputer programs for long-term tobramycin therapy. Hatton RC; Massey KL; Russell WL Ther Drug Monit; 1984; 6(4):432-7. PubMed ID: 6549085 [TBL] [Abstract][Full Text] [Related]
51. Tobramycin population pharmacokinetics in neonates. de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN Clin Pharmacol Ther; 1997 Oct; 62(4):392-9. PubMed ID: 9357390 [TBL] [Abstract][Full Text] [Related]
52. Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. Crass RL; Ross BE; Derstine BA; Lichty M; Sullivan JA; Su GL; Wang SC; Pai MP Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632017 [TBL] [Abstract][Full Text] [Related]
53. Validation of the use of Bayesian analysis in the optimization of gentamicin therapy from the commencement of dosing. Chrystyn H Drug Intell Clin Pharm; 1988 Jan; 22(1):49-53. PubMed ID: 3349920 [TBL] [Abstract][Full Text] [Related]
54. Carbenicillin inactivation of aminoglycosides in patients with severe renal failure. Weibert R; Keane W; Shapiro F Trans Am Soc Artif Intern Organs; 1976; 22():439-43. PubMed ID: 951863 [TBL] [Abstract][Full Text] [Related]
56. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Hermida J; Tutor JC Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715 [TBL] [Abstract][Full Text] [Related]
57. Effect of body weight on aminoglycoside pharmacokinetics in patients with hypoalbuminemia. Kale-Pradhan PB; Buckler V; Bush PW Am J Health Syst Pharm; 1997 Oct; 54(19):2201-3. PubMed ID: 9331441 [No Abstract] [Full Text] [Related]